Needle-free influenza vaccination.

[1]  M. Rock,et al.  Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Ambrozaitis,et al.  Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial , 2010, Human vaccines.

[3]  L. Babiuk,et al.  Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. , 2010, Vaccine.

[4]  M. Prausnitz,et al.  Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. , 2010, The Journal of infectious diseases.

[5]  A. Osterhaus,et al.  Animal models for the preclinical evaluation of candidate influenza vaccines , 2010, Expert review of vaccines.

[6]  M. Zambon,et al.  Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. , 2009, Vaccine.

[7]  P. van Damme,et al.  Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. , 2009, Vaccine.

[8]  H. Shiota,et al.  Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. , 2009, Vaccine.

[9]  Kwok-Hung Chan,et al.  Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. , 2009, Vaccine.

[10]  C. Herzog,et al.  Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. , 2009, Vaccine.

[11]  G. Rimmelzwaan,et al.  Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. , 2009, Vaccine.

[12]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[13]  S. Oh,et al.  Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer , 2009, Journal of Medical Virology.

[14]  M. Prausnitz,et al.  Transdermal Influenza Immunization with Vaccine-Coated Microneedle Arrays , 2009, PLoS ONE.

[15]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[16]  H. Frijlink,et al.  Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[17]  K. Snibson,et al.  Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing , 2008, Mucosal Immunology.

[18]  F. de Looze,et al.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. , 2008, The Journal of infectious diseases.

[19]  Katherine A. Fitzgerald,et al.  Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling , 2008, PLoS pathogens.

[20]  J. Oxford,et al.  Animal models in influenza vaccine testing , 2008, Expert review of vaccines.

[21]  R. Rappuoli,et al.  Molecular and cellular signatures of human vaccine adjuvants , 2008, Proceedings of the National Academy of Sciences.

[22]  Y. Maeno,et al.  Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. , 2008, Vaccine.

[23]  F. Batista,et al.  New insights into the early molecular events underlying B cell activation. , 2008, Immunity.

[24]  E. Hamelmann,et al.  Influenza virus; , 2008 .

[25]  Jung-Hwan Park,et al.  Dissolving microneedles for transdermal drug delivery. , 2008, Biomaterials.

[26]  W. Hinrichs,et al.  Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities , 2008, Pharmaceutical Research.

[27]  C. Czerkinsky,et al.  Sublingual vaccination with influenza virus protects mice against lethal viral infection , 2008, Proceedings of the National Academy of Sciences.

[28]  C. Katlama,et al.  Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans1 , 2008, The Journal of Immunology.

[29]  I. Šterzl,et al.  Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant. , 2008, Immunology letters.

[30]  W. Hinrichs,et al.  Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. , 2007, Vaccine.

[31]  W. Hinrichs,et al.  Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. , 2007, Vaccine.

[32]  C. Czerkinsky,et al.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. , 2007, Vaccine.

[33]  A. Osterhaus,et al.  Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. , 2007, Current opinion in biotechnology.

[34]  T. Ichinohe,et al.  Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine , 2007, The Journal of infectious diseases.

[35]  J. Renauld,et al.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response , 2007, Immunology.

[36]  A. Rawat,et al.  A needle-free approach for topical immunization: antigen delivery via vesicular carrier system(s). , 2007, Current Medicinal Chemistry.

[37]  H. Staats,et al.  Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination , 2007, AAPS PharmSciTech.

[38]  G. Glenn,et al.  Adjuvants: progress, regress and pandemic preparedness , 2007, Expert Review of Vaccines.

[39]  G. Glenn,et al.  Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch , 2007, Expert review of vaccines.

[40]  S. Rijpkema,et al.  New adjuvants: EU regulatory developments , 2007, Expert review of vaccines.

[41]  P. Jensen.  Recent advances in antigen processing and presentation , 2007, Nature Immunology.

[42]  F. Newman,et al.  Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. , 2007, Vaccine.

[43]  Gideon Kersten,et al.  Needle-free vaccine delivery , 2007, Expert opinion on drug delivery.

[44]  T. Ichinohe,et al.  Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. , 2007, Microbes and infection.

[45]  Seong Kyu Song,et al.  Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice. , 2007, Vaccine.

[46]  S. Gringhuis,et al.  Innate signaling and regulation of Dendritic cell immunity. , 2007, Current opinion in immunology.

[47]  R. Couch,et al.  A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. , 2007, Vaccine.

[48]  S. Ko,et al.  A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. , 2007, Vaccine.

[49]  Kwok-Hung Chan,et al.  Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children , 2007, Pediatrics.

[50]  Zhu Guo,et al.  Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice , 2007, Clinical and Vaccine Immunology.

[51]  B. Laube,et al.  Devices for aerosol delivery to treat sinusitis. , 2007, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[52]  A. Hickey,et al.  Pulmonary vaccine delivery , 2007, Expert review of vaccines.

[53]  Mark R. Prausnitz,et al.  Coating Formulations for Microneedles , 2007, Pharmaceutical Research.

[54]  N. Harvey,et al.  Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines , 2007, Clinical and Vaccine Immunology.

[55]  Chun-Ming Huang.  Topical vaccination: the skin as a unique portal to adaptive immune responses , 2007, Seminars in Immunopathology.

[56]  P. Thongcharoen,et al.  Antibody responses after dose-sparing intradermal influenza vaccination. , 2007, Vaccine.

[57]  H. Junginger,et al.  N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. , 2007, Vaccine.

[58]  A. Vaheri,et al.  Search for Herpesviruses in cerebrospinal fluid of facial palsy patients by PCR , 2007, Acta oto-laryngologica.

[59]  W. Hinrichs,et al.  Preservation of Influenza Virosome Structure and Function During Freeze-Drying and Storage , 2007, Journal of liposome research.

[60]  U. Wahn,et al.  Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With Asthma , 2006, The Pediatric infectious disease journal.

[61]  D. Lewis,et al.  Cellular Immune Responses in Children and Adults Receiving Inactivated or Live Attenuated Influenza Vaccines , 2006, Journal of Virology.

[62]  S. Mitragotri,et al.  Needle-free liquid jet injections: mechanisms and applications , 2006, Expert review of medical devices.

[63]  Andrea Gazzaniga,et al.  Time-controlled oral delivery systems for colon targeting , 2006, Expert opinion on drug delivery.

[64]  R. Compans,et al.  Transcutaneous immunization with inactivated influenza virus induces protective immune responses. , 2006, Vaccine.

[65]  K. Haeussinger,et al.  Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. , 2006, Vaccine.

[66]  Samir Mitragotri,et al.  Current status and future prospects of needle-free liquid jet injectors , 2006, Nature Reviews Drug Discovery.

[67]  T. Welte,et al.  Novel strategies of aerosolic pharmacotherapy. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[68]  C. Ewen,et al.  T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly1 , 2006, The Journal of Immunology.

[69]  R. Bugarini,et al.  Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers , 2006, Journal of Virology.

[70]  Y. Barenholz,et al.  A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. , 2006, Vaccine.

[71]  S. Edwards,et al.  Local immune responses following nasal delivery of an adjuvanted influenza vaccine. , 2006, Vaccine.

[72]  James D. Campbell,et al.  Needle-free vaccine delivery. , 2006, Advanced drug delivery reviews.

[73]  I. Donatelli,et al.  Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. , 2006, Vaccine.

[74]  C. Shiboski,et al.  Overview and Research Agenda Arising from the Sixth World Workshop on Oral Health and Disease in AIDS , 2006, Advances in Dental Research.

[75]  Y. Rojanasakul,et al.  Vaccine delivery--current trends and future. , 2006, Current drug delivery.

[76]  K. Lövgren,et al.  The Combined CTA1-DD/ISCOM Adjuvant Vector Promotes Priming of Mucosal and Systemic Immunity to Incorporated Antigens by Specific Targeting of B Cells1 , 2006, The Journal of Immunology.

[77]  Vincent J. Sullivan,et al.  Formulation of a dry powder influenza vaccine for nasal delivery , 2006, AAPS PharmSciTech.

[78]  R. Rappuoli,et al.  Oral Spray Immunization May Be an Alternative to Intranasal Vaccine Delivery to Induce Systemic Antibodies but not Nasal Mucosal or Cellular Immunity , 2006, Scandinavian journal of immunology.

[79]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[80]  H. Kido,et al.  Modified Pulmonary Surfactant Is a Potent Adjuvant That Stimulates the Mucosal IgA Production in Response to the Influenza Virus Antigen1 , 2006, The Journal of Immunology.

[81]  Vincent J. Sullivan,et al.  Noninvasive delivery technologies: respiratory delivery of vaccines , 2006, Expert opinion on drug delivery.

[82]  Samir Mitragotri,et al.  Immunization without needles , 2005, Nature Reviews Immunology.

[83]  R. Rappuoli,et al.  Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan , 2005, Infection and Immunity.

[84]  P. Welling,et al.  In vivo evaluation of nicotine lyophilised nasal insert in sheep. , 2005, International journal of pharmaceutics.

[85]  R. Kinget,et al.  Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. , 2005, Advanced drug delivery reviews.

[86]  J. Mcghee,et al.  Enterotoxin-Based Mucosal Adjuvants Alter Antigen Trafficking and Induce Inflammatory Responses in the Nasal Tract , 2005, Infection and Immunity.

[87]  S. Ko,et al.  α-Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor1 , 2005, The Journal of Immunology.

[88]  R. Read,et al.  Effective nasal influenza vaccine delivery using chitosan. , 2005, Vaccine.

[89]  P. Holt,et al.  Anatomical Location Determines the Distribution and Function of Dendritic Cells and Other APCs in the Respiratory Tract1 , 2005, The Journal of Immunology.

[90]  J. Wilschut,et al.  The virosome concept for influenza vaccines. , 2005, Vaccine.

[91]  I. Donatelli,et al.  Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. , 2005, Vaccine.

[92]  Jan Holmgren,et al.  Mucosal immunity and vaccines , 2005, Nature Medicine.

[93]  R. Rappuoli,et al.  A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants , 2005, Human vaccines.

[94]  H. Frijlink,et al.  Trends in the technology-driven development of new inhalation devices. , 2005, Drug discovery today. Technologies.

[95]  T. Ichinohe,et al.  Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant , 2005, Journal of medical virology.

[96]  S. Halperin,et al.  A Phase I, Randomized, Controlled Trial to Study the Reactogenicity and Immunogenicity of a Nasal, Inactivated Trivalent Influenza Virus Vaccine in Healthy Adults , 2005, Human vaccines.

[97]  Vincent J. Sullivan,et al.  A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. , 2004, Vaccine.

[98]  Dexiang Chen,et al.  Epidermal powder immunization against influenza. , 2004, Vaccine.

[99]  J. Stoddard,et al.  Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine , 2004, Expert review of vaccines.

[100]  G. Glenn,et al.  Dose sparing with intradermal injection of influenza vaccine. , 2004, The New England journal of medicine.

[101]  F. Newman,et al.  Serum antibody responses after intradermal vaccination against influenza. , 2004, The New England journal of medicine.

[102]  Y. Iwakura,et al.  Secretory IgA antibodies provide cross‐protection against infection with different strains of influenza B virus , 2004, Journal of medical virology.

[103]  T. Voshaar,et al.  A review of the development of Respimat Soft Mist Inhaler. , 2004, International journal of pharmaceutics.

[104]  R. Rappuoli,et al.  Novel Approaches to Vaccine Delivery , 2004, Pharmaceutical Research.

[105]  M. Tafaghodi,et al.  Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. , 2004, International journal of pharmaceutics.

[106]  D. Engelhard,et al.  Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. , 2004, Vaccine.

[107]  M. Battegay,et al.  Intranasal influenza vaccine in a working population. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[109]  R. Cox,et al.  Influenza Virus: Immunity and Vaccination Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated Influenza Vaccines , 2004, Scandinavian journal of immunology.

[110]  Mark G. Allen,et al.  Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[111]  G. Glenn,et al.  Transcutaneous immunization and immunostimulant strategies. , 2003, Immunology and allergy clinics of North America.

[112]  Y. Maa,et al.  Epidermal powder immunization of mice and monkeys with an influenza vaccine. , 2003, Vaccine.

[113]  A. Bot,et al.  Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. , 2003, Vaccine.

[114]  M. Muszkat,et al.  Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. , 2003, Vaccine.

[115]  G. Canonica,et al.  Noninjection routes for immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[116]  S. Rockman,et al.  Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. , 2003, Vaccine.

[117]  D. O'hagan,et al.  Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[118]  Y. Barenholz,et al.  Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. , 2002, Vaccine.

[119]  Y. Maa,et al.  Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. , 2002, Vaccine.

[120]  P. Wyde,et al.  Modulation of γδ T cells in mouse buccal epithelium following antigen priming , 2002 .

[121]  Diane E. Sutter,et al.  Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery , 2002, Nature Medicine.

[122]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[123]  J. Katz,et al.  Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. , 2002, Vaccine.

[124]  A. Morag,et al.  Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. , 2002, Vaccine.

[125]  Dexiang Chen,et al.  Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses , 2001, Journal of Virology.

[126]  R. Glueck.  Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. , 2001, Vaccine.

[127]  M. Plante,et al.  Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. , 2001, Vaccine.

[128]  H. Hoogsteden,et al.  Lung dendritic cells and host immunity to infection. , 2001, The European respiratory journal.

[129]  S. Michalek,et al.  Human salivary immunoglobulin and antigen-specific antibody activity after tonsillectomy. , 2001, Oral microbiology and immunology.

[130]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[131]  B. Morein,et al.  Immunostimulating complexes (ISCOMs) for nasal vaccination. , 2001, Advanced drug delivery reviews.

[132]  F. Newman,et al.  Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. , 2001, Vaccine.

[133]  Dexiang Chen,et al.  Serum and Mucosal Immune Responses to an Inactivated Influenza Virus Vaccine Induced by Epidermal Powder Immunization , 2001, Journal of Virology.

[134]  D. Wise,et al.  Facilitated Intranasal Induction of Mucosal and Systemic Immunity to Mutans Streptococcal Glucosyltransferase Peptide Vaccines , 2001, Infection and Immunity.

[135]  M. Pearse,et al.  Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. , 2001, Vaccine.

[136]  J. Clements,et al.  Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. , 2001, Vaccine.

[137]  T. Tumpey,et al.  Mucosal Delivery of Inactivated Influenza Vaccine Induces B-Cell-Dependent Heterosubtypic Cross-Protection against Lethal Influenza A H5N1 Virus Infection , 2001, Journal of Virology.

[138]  S. Şenel,et al.  Delivery of bioactive peptides and proteins across oral (buccal) mucosa. , 2001, Current pharmaceutical biotechnology.

[139]  L. Perino,et al.  Efficacy of intradermal vaccination. , 2001, Veterinary immunology and immunopathology.

[140]  G. Ott,et al.  Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization , 2001, Clinical Diagnostic Laboratory Immunology.

[141]  J. Wilschut,et al.  Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. , 2001, Vaccine.

[142]  J. Brewer,et al.  Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). , 2001, Vaccine.

[143]  K. Komase,et al.  Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. , 2001, Vaccine.

[144]  B. Guy,et al.  Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. , 2001, Vaccine.

[145]  H. Davis,et al.  Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. , 2000, Vaccine.

[146]  M. Roberts,et al.  Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.

[147]  Y. Kawaoka,et al.  Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.

[148]  K. Neuzil,et al.  Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. , 2000, Vaccine.

[149]  J. S. Abramson.  Intranasal, cold-adapted, live, attenuated influenza vaccine. , 1999, The Pediatric Infectious Disease Journal.

[150]  B. Arulanandam,et al.  Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. , 1999, The Journal of infectious diseases.

[151]  R. Glück,et al.  Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers , 1999, Journal of Virology.

[152]  A. Gebert,et al.  M cells at locations outside the gut. , 1999, Seminars in immunology.

[153]  R. Rappuoli,et al.  The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. , 1999, Vaccine.

[154]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[155]  E. Scott,et al.  Design and delivery of non-parenteral vaccines. , 1998, Journal of clinical pharmacy and therapeutics.

[156]  M. Vidgrén,et al.  Nasal delivery systems and their effect on deposition and absorption. , 1998, Advanced drug delivery reviews.

[157]  B. Bellhouse,et al.  Bioavailability following transdermal powdered delivery (TPD) of radiolabeled inulin to hairless guinea pigs , 1997 .

[158]  S. Young,et al.  Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. , 1997, The Journal of infectious diseases.

[159]  E. M. Sorokin,et al.  Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization. , 1996, Journal of biotechnology.

[160]  R. Yu,et al.  Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy , 1994, The British journal of dermatology.

[161]  C. Meitin,et al.  Enteric immunization of mice against influenza with recombinant vaccinia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[162]  C. Czerkinsky,et al.  Mucosal immunity: implications for vaccine development. , 1992, Immunobiology.

[163]  P. Small,et al.  Immunoglobulin A mediation of murine nasal anti-influenza virus immunity , 1991, Journal of Virology.

[164]  K. Lövgren,et al.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration , 1990, Clinical and experimental immunology.

[165]  B. Murphy,et al.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus , 1986, Journal of clinical microbiology.

[166]  R. W. Howell,et al.  A comparative trial of influenza immunization by inhalation and hypojet methods. , 1973, Practitioner.

[167]  R. Ganguly,et al.  Immune response of the human respiratory tract. I. Immunoglobulin levels and influenza virus vaccine antibody response. , 1973, Journal of immunology.

[168]  R. Waldman,et al.  Specificity of respiratory secretion antibody against influenza virus. , 1970, Journal of immunology.

[169]  P. Small,et al.  Immunization Against Influenza: Prevention of Illness in Man by Aerosolized Inactivated Vaccine , 1969 .

[170]  J. Kasel,et al.  Influenza Antibody in Human Respiratory Secretions after Subcutaneous or Respiratory Immunization with Inactivated Virus , 1968, Nature.

[171]  J. Kasel,et al.  Antibody response in respiratory secretions of volunteers given live and dead influenza virus. , 1968, Journal of immunology.

[172]  J. Kasel,et al.  Influenza virus neutralizing antibody in human respiratory secretions. , 1968, Journal of immunology.

[173]  H. Frijlink,et al.  5 Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept ( Twincer ® ) for high powder doses , 2009 .

[174]  A. Ludwig,et al.  Microneedles for transdermal drug delivery: a minireview. , 2008, Frontiers in bioscience : a journal and virtual library.

[175]  Vincent J. Sullivan,et al.  Anthrax vaccine powder formulations for nasal mucosal delivery. , 2006, Journal of pharmaceutical sciences.

[176]  G. Glenn,et al.  Mass vaccination: solutions in the skin. , 2006, Current topics in microbiology and immunology.

[177]  P. Holt,et al.  Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract. , 2005, Proceedings of the American Thoracic Society.

[178]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[179]  S. Newman,et al.  Drug delivery to the nasal cavity: in vitro and in vivo assessment. , 2004, Critical reviews in therapeutic drug carrier systems.

[180]  W. P. Glezen,et al.  Control of influenza. , 2004, Texas Heart Institute journal.

[181]  J. Treanor,et al.  Immune correlates of protection against influenza in the human challenge model. , 2003, Developments in biologicals.

[182]  Robert T. Chen,et al.  Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. , 2002, Bulletin of the World Health Organization.

[183]  B. Murphy,et al.  Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. , 1995, Vaccine.

[184]  E. Walsh,et al.  Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. , 1994, Vaccine.

[185]  K. Bergmann,et al.  Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine. , 1986, International archives of allergy and applied immunology.

[186]  R. Khakoo,et al.  Immunization against influenza in humans using an oral enteric-coated killed virus vaccine. , 1984, Journal of biological standardization.

[187]  F. Liew,et al.  Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity , 1984, European journal of immunology.

[188]  R. W. Howell,et al.  The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant. , 1973, The Journal of the Society of Occupational Medicine.